Compare Enveric Biosciences Inc (ENVB) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Carparts.Com Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Carparts.Com Inc trades at $8.51 (market cap $66.42M). The key difference: Carparts.Com Inc is far larger — about 9.8× Enveric Biosciences Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Carparts.Com Inc for 45 Days on average.
| ENVB | PRTS | |
|---|---|---|
Market Cap | $6.80M | $66.42M |
Volume | 64,867 | 40,287 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $10.00 |
52-Week Low | $1.27 | $3.88 |
Typical Hold Time | 14 Days | 45 Days |
Enterprise Value | -$1.49M | $79.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
CarParts.com (PRTS) trades at $8.695, up 0.99% on the day, with a bullish technical outlook supported by positive moving average signals. The company shows improving quarterly earnings performance, beating estimates in recent quarters, though it remains unprofitable with negative margins. Analyst sentiment is positive with 60% buy ratings, while recent news highlights the company's data-driven competitive strategy in the auto parts e-commerce sector.
The stock presents a speculative opportunity given its low P/S ratio of 0.11 and consistent earnings beats, but faces significant fundamental challenges including negative cash flow, declining revenue trends, and persistent losses. Key risks include execution challenges in achieving profitability and competitive pressures in the online auto parts market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
